Preclinical and phase 1/2 data of the CHK1 inhibitor BBI-355 in development for esophageal and gastric cancers (EGC) with EGFR or FGFR2 amplifications Meeting Abstract
| Authors: | Maron, S. B.; Sharma, M. R.; Spira, A. I.; Rodriguez Rivera, I. I.; Chawla, S. P.; Philipovskiy, A.; Johnson, M. L.; Falchook, G. S.; Wainberg, Z. A.; Hansen, R.; Weymer, S.; Wagner, K.; Yap, T. A. |
| Abstract Title: | Preclinical and phase 1/2 data of the CHK1 inhibitor BBI-355 in development for esophageal and gastric cancers (EGC) with EGFR or FGFR2 amplifications |
| Meeting Title: | 2025 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2025 Jan 23-25 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-02-01 |
| DOI: | 10.1200/JCO.2025.43.4_suppl.TPS517 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl plus with full text |
| DOI/URL: | |
| Notes: | Meeting abstract: TPS517 -- Source: CINAHL Plus with Full Text |
